drugset / Trial / NCT02780115

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02780115

Phase 2 Completed 151 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).

Timeline

Start
2016-05-26
Primary completion
2017-10-31
Completion
2017-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-190584 Unknown Other
Subject Oxymetazoline Other / unclassified Other

Indications